KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Invested Capital (2018 - 2025)

Aurinia Pharmaceuticals' Invested Capital history spans 8 years, with the latest figure at $650.2 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 44.46% year-over-year to $650.2 million; the TTM value through Dec 2025 reached $650.2 million, up 44.46%, while the annual FY2025 figure was $650.2 million, 44.46% up from the prior year.
  • Invested Capital reached $650.2 million in Q4 2025 per AUPH's latest filing, up from $437.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $650.2 million in Q4 2025 to a low of $298.2 million in Q3 2021.
  • Average Invested Capital over 5 years is $436.3 million, with a median of $439.2 million recorded in 2024.
  • Peak YoY movement for Invested Capital: dropped 27.17% in 2021, then skyrocketed 44.46% in 2025.
  • A 5-year view of Invested Capital shows it stood at $479.1 million in 2021, then decreased by 15.37% to $405.4 million in 2022, then rose by 15.44% to $468.1 million in 2023, then dropped by 3.84% to $450.1 million in 2024, then surged by 44.46% to $650.2 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Invested Capital are $650.2 million (Q4 2025), $437.8 million (Q3 2025), and $410.8 million (Q2 2025).